Q2 2026 Perimeter Medical Imaging AI Inc Earnings Call Transcript
Key Points
- Perimeter Medical Imaging AI Inc (PYNKF) achieved 31% sequential growth in recurring revenue in Q2 2026, driven by S-Series consumables and leases.
- The company successfully reduced operating expenses by 28% and net loss by 33% year-over-year, demonstrating effective cost management.
- FDA PMA approval for the next-generation Claire device was obtained in March 2026, enabling commercial deployment.
- Two Claire systems have been placed and are already performing procedures, with the first hospital commercially deploying the technology.
- The company has built a strong sales funnel, including existing S-Series users upgrading to Claire and new customers, positioning for accelerated growth in 2027.
- Perimeter Medical Imaging AI Inc (PYNKF) faces delays in Claire adoption due to hospital AI review committees, which require extensive education and navigation.
- The company's cash position is limited at $6.4 million, providing only about 12 months of runway, which may constrain growth initiatives.
- Revenue growth is uncertain, with management unable to confirm if the 2-3x growth target for 2026 will be met due to timing of sales closures.
- The sales team expansion is still in progress, with new hires not expected to contribute to revenue until late 2026 or early 2027.
- The company's reliance on a small commercial team and the need to convert existing S-Series customers to Claire may slow market penetration.
Good afternoon, ladies and gentlemen, and welcome to Perimeter Medical Q2 2026 Conference Call. (Operator Instructions) This call is being recorded on Tuesday, August 18, 2026.
I would now like to turn the conference over to Stephen Kilmer, Investor Relations. Please go ahead.
Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws. These may include statements regarding the future financial position, business strategy and strategic goals, commercial activities and timing, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, the potential benefits of our products, including Perimeter S-Series OCT and Claire OCT + AI. Perimeter's ability to broaden its user base and system utilization, expectations regarding new products and the timing thereof and expectations regarding
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
